---
title: A Study of ATB1651 in Adults With Mild to Moderate Onychomycosis
nct_id: NCT05089409
overall_status: COMPLETED
phase: PHASE1
sponsor: AmtixBio Co., Ltd.
study_type: INTERVENTIONAL
primary_condition: Onychomycosis
countries: New Zealand
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT05089409.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT05089409"
ct_last_update_post_date: 2023-10-11
last_seen_at: "2026-05-12T06:36:37.285Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# A Study of ATB1651 in Adults With Mild to Moderate Onychomycosis

**Official Title:** A Phase 1, First in Human, Randomized, Double-Blind, Placebo-Controlled Multiple Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of ATB1651 in Adults With Mild to Moderate Onychomycosis

**NCT ID:** [NCT05089409](https://clinicaltrials.gov/study/NCT05089409)

## Key Facts

- **Status:** COMPLETED
- **Phase:** PHASE1
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 30
- **Lead Sponsor:** AmtixBio Co., Ltd.
- **Collaborators:** Novotech (Australia) Pty Limited
- **Conditions:** Onychomycosis
- **Start Date:** 2022-03-04
- **Completion Date:** 2023-09-20
- **CT.gov Last Update:** 2023-10-11

## Brief Summary

The study is designed to evaluate the Safety, Tolerability and Pharmacokinetics of ATB1651 in participants with mild to moderate onychomycosis.

## Detailed Description

Onychomycosis (also known as tinea unguium) is a contagious infection of toe nails by fungal organisms including dermatophytes, yeast, and molds.

This is phase 1, first in human, randomized, double-blind, placebo-controlled, MAD study designed to assess the safety, tolerability, and PK of ATB1651 when administered in participants with mild to moderate onychomycosis.

The study consists of 2 parts. In both parts, participants will receive multiple doses of ATB1651 applied to 1 affected great toenail and the remaining toenails (affected or not)

Part A: Participants will be enrolled into 1 of 3 cohorts and randomized to receive either ATB1651 or placebo at a ratio of 2:1.

Up to 2 additional cohorts may be added at the discretion of the Sponsor and Safety Monitoring Committee, if deemed necessary

Part B: Participants will be randomized within a single cohort to receive either ATB1651 or placebo at a ratio of 4:1

There will be 18 participants enrolled in part A, 30 participants in part B

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 65 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

1. Confirmation of onychomycosis by mycological staining and/or culture from affected great toenail(s).
2. Appearance of onychomycosis involving 20% to 70% of 1 (or both) affected great toenail(s) as determined by visual inspection after the nail has been trimmed. If the percentage of infection is outside this range but is still considered appropriate for this study, based on the overall impression of the Investigator, participation can be considered in consultation with the Medical Monitor.
3. The combined thickness of the distal nail plate at the associated hyperkeratotic nail bed is less than 3 mm.
4. Medically healthy with clinically insignificant Screening results (eg, laboratory profiles, medical history, ECGs, physical exam), as judged by the PI.
5. Negative urine drug screen and alcohol breath test at Screening and Day 1.
6. Body Mass Index (BMI) between 17.5 and 35.0, inclusive.
7. Agree to adhere to the current state and national advice regarding minimizing exposure to coronavirus disease of 2019 (COVID-19) from the Screening visit until the EOS visit.

Exclusion Criteria:

1. History of allergy to any of the excipients in ATB1651.
2. Positive COVID-19 test at Screening or any symptoms consistent with COVID-19 prior to initial dosing.
3. Positive test for hepatitis C antibody (HCV), hepatitis B surface antigen (HBsAg), or human immunodeficiency virus (HIV) antibody at Screening.
4. Have any underlying physical or psychological medical conditions that, in the opinion of the Investigator, would make it unlikely that the participant will comply with the study.
5. Pregnant or lactating at Screening or planning to become pregnant (self or partner) at any time during the study, including the follow-up period.
6. Unwilling to refrain from the use of nail cosmetics such as clear and/ or colored nail lacquers from the Screening visit until the end of the study.
7. Use of any IP or investigational medical device within 30 days prior to Screening, or 5 half-lives of the product (whichever is the longest) or participation in more than 4 investigational drug studies within 1 year prior to Screening.
```

## Arms

- **A (ATB1651, 2 mg/mL)** (EXPERIMENTAL) — The planned ATB1651 dose level of 2 mg/mL.

Six participants are expected to be enrolled in each arm.
- **B (ATB1651, 5 mg/mL)** (EXPERIMENTAL) — The planned ATB1651 dose level of 5 mg/mL.

Six participants are expected to be enrolled in each arm.
- **C (ATB1651, 10 mg/mL)** (EXPERIMENTAL) — The planned ATB1651 dose level of 10 mg/mL.

Six participants are expected to be enrolled in each arm.
- **D (ATB1651, 20 mg/mL)** (EXPERIMENTAL) — The planned ATB1651 dose level of 20 mg/mL.

Six participants are expected to be enrolled in each arm.
- **E (ATB1651, 30 mg/mL)** (PLACEBO_COMPARATOR) — The planned ATB1651 dose level of 30 mg/mL.

Six participants are expected to be enrolled in each arm.
- **F (placebo)** (PLACEBO_COMPARATOR) — The participants will apply placebo for 28 days.

Six participants are expected to be enrolled in each arm.

## Interventions

- **ATB1651, 2 mg/mL** (DRUG) — The participants will apply daily doses of ATB1651, 2 mg/mL to all 10 toenails including at least 1 affected great toenail for 28 days
- **ATB1651, 5 mg/mL** (DRUG) — The participants will apply daily doses of ATB1651, 5 mg/mL to all 10 toenails including at least 1 affected great toenail for 28 days
- **ATB1651, 10 mg/mL** (DRUG) — The participants will apply daily doses of ATB1651, 10 mg/mL to all 10 toenails including at least 1 affected great toenail for 28 days
- **ATB1651, 20 mg/mL** (DRUG) — The participants will apply daily doses of ATB1651, 20 mg/mL to all 10 toenails including at least 1 affected great toenail for 28 days
- **ATB1651, 30 mg/mL** (DRUG) — The participants will apply daily doses of ATB1651, 30 mg/mL to all 10 toenails including at least 1 affected great toenail for 28 days
- **Placebo** (OTHER) — The participants will apply placebo to all 10 toenails including at least 1 affected great toenail for 28 days

## Primary Outcomes

- **To assess the safety and tolerability of multiple ascending doses (MAD) of ATB1651 in participants with mild to moderate onychomycosis through the percentage and severity of adverse events including pain, erythema and local irritation** _(time frame: From baseline to end of study treatment up to 56 days)_ — Adverse Events will be coded using the most current version of Medical Dictionary for Regulatory Activities (MedDRA®) Version 22.0 or higher

## Secondary Outcomes

- **To assess the efficacy of ATB1651 in improving signs and symptoms of onychomycosis in participants with mild to moderate onychomycosis** _(time frame: From baseline to end of study treatment up to 56 days)_
- **To assess the efficacy of ATB1651 in improving signs and symptoms of onychomycosis in participants with mild to moderate onychomycosis** _(time frame: From baseline to end of study treatment up to 56 days)_
- **To assess whether there is systemic exposure following multiple doses of ATB1651 through pharmacokinetic analysis Parameters: Maximum plasma concentration and Time to maximum plasma concentration** _(time frame: From baseline to end of study treatment up to 56 days)_
- **To assess whether there is systemic exposure following multiple doses of ATB1651 through pharmacokinetic analysis Parameters: Apparent terminal elimination rate constant** _(time frame: From baseline to end of study treatment up to 56 days)_
- **To assess whether there is systemic exposure following multiple doses of ATB1651 through pharmacokinetic analysis Parameters: Area under the drug concentration-time curve, from time zero to 24 hours post dose** _(time frame: From baseline to end of study treatment up to 56 days)_
- **To assess whether there is systemic exposure following multiple doses of ATB1651 through pharmacokinetic analysis Parameters: Area under the drug concentration-time curve, from time zero to the last measurable concentration** _(time frame: From baseline to end of study treatment up to 56 days)_
- **To assess whether there is systemic exposure following multiple doses of ATB1651 through pharmacokinetic analysis Parameters: Area under the drug concentration-time curve, from time zero to infinity** _(time frame: From baseline to end of study treatment up to 56 days)_
- **To assess whether there is systemic exposure following multiple doses of ATB1651 through pharmacokinetic analysis Parameters: Apparent terminal half-life** _(time frame: From baseline to end of study treatment up to 56 days)_
- **To assess whether there is systemic exposure following multiple doses of ATB1651 through pharmacokinetic analysis Parameters: Apparent clearance** _(time frame: From baseline to end of study treatment up to 56 days)_
- **To assess whether there is systemic exposure following multiple doses of ATB1651 through pharmacokinetic analysis Parameters: Apparent terminal volume of distribution** _(time frame: From baseline to end of study treatment up to 56 days)_
- **To assess whether there is systemic exposure following multiple doses of ATB1651 through pharmacokinetic analysis Parameters: Plasma ATB1651 trough concentrations (Ctrough) during multiple dosing** _(time frame: From baseline to end of study treatment up to 56 days)_

## Locations (1)

- New Zealand Clinical Research Christchurch, Christchurch, New Zealand

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `sponsor.collaborators` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.new zealand clinical research christchurch|christchurch||new zealand` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT05089409.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT05089409*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*